Compassionate Use of Omegaven® in the Treatment of Parenteral Nutrition Induced Hepatic Injury
Status:
Terminated
Trial end date:
2017-04-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to make Omegaven® available to cancer patients with liver
disease and to determine if Omegaven® can improve or prevent further liver disease. The study
will also look at the effects Omegaven® has on immune function.